StockData
Novartis AG logo

Novartis AG

NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 4, 2026Score 7/30
$161.52+0.73 (+0.45%)

Close on Nov 2, 2026Market cap $308.20BP/E 22.6Yield –

Novartis Reported Net Sales Growth in USD by Year

Reported Net Sales Growth in USD (% YoY USD) (%)

Novartis Reported Net Sales Growth in USD: 8.0% in FY2025, down 3.0 pts from a year earlier.

Latest, FY2025
8.0%
Period ended Dec 31, 2025
Change on a year earlier
-3.0 pts
11.0% in FY2024
History
3 years
Since FY2023
Sources
3
Documents cited below

Where the FY2025 figure comes from

“|| Total net sales to third parties | 54 532 | 50 317 | 8 | 8”

Source: Novartis Form 6-K (0001114448-26-000007) ↗

Reported in Form 6-K & Form 20-F.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedReported Net Sales Growth in USD (% YoY USD) (%)Year on yearSource
FY2025Dec 31, 20258.0%-3.0 ptsNovartis Form 6-K (0001114448-26-000007) ↗
FY2024Dec 31, 202411.0%+3.0 ptsNovartis Form 6-K (0001370368-25-000007) ↗
FY2023Dec 31, 20238.0%–Novartis Form 6-K (0001370368-24-000007) ↗

Cite this data

StockData. (2026). Novartis Reported Net Sales Growth in USD (%), annual FY2023–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/net-sales-yoy-usd-pct

See every metric in the Novartis KPI table. Data updated Nov 2, 2026.